BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

31 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success

29 Mar 2023 16:01:31 By Nasdaq GlobeNewswire

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

08 Mar 2023 15:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Mar 2023 07:00:13 By Nasdaq GlobeNewswire

BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)

24 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

22 Feb 2023 07:00:04 By Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

21 Feb 2023 07:00:23 By Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

07 Feb 2023 07:00:16 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2023 07:00:30 By Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

03 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

26 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

23 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

09 Jan 2023 07:05:55 By Nasdaq GlobeNewswire

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

09 Jan 2023 07:00:40 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jan 2023 07:00:28 By Nasdaq GlobeNewswire

BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:00:46 By Nasdaq GlobeNewswire

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

15 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Dec 2022 16:01:09 By Nasdaq GlobeNewswire

BioCryst to Present at JMP Securities Hematology & Oncology Summit

05 Dec 2022 07:00:26 By Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

28 Nov 2022 07:00:43 By Nasdaq GlobeNewswire